Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention

被引：0
|
作者：
Itziar Oyagüez
Carmen Suárez
José Luis López-Sendón
José Ramón González-Juanatey
Fernando de Andrés-Nogales
Jorge Suárez
Carlos Polanco
Javier Soto
机构：
[1] Pharmacoeconomics and Outcomes Research Iberia (PORIB),Internal Medicine Department
[2] Hospital La Princesa,Cardiology Department
[3] Hospital Universitario La Paz,Cardiology Department
[4] IdiPaz,undefined
[5] CIBER-CV,undefined
[6] Complejo Hospitalario Universitario de Compostela,undefined
[7] Bristol-Myers Squibb,undefined
[8] Pfizer,undefined
来源：
PharmacoEconomics - Open | 2020年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：485 / 497
页数：12
相关论文
共 50 条
  • [21] Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan
    Kamae, Isao
    Hashimoto, Yoichiro
    Koretsune, Yukihiro
    Tanahashi, Norio
    Murata, Tatsunori
    Phatak, Hemant
    Liu, Larry Z.
    Tang, Ann C.
    Wang, Peter Feng
    Okumura, Ken
    CLINICAL THERAPEUTICS, 2015, 37 (12) : 2837 - 2851
  • [22] COST-EFFECTIVENESS ANALYSIS OF APIXABAN COMPARED TO OTHER DOACS FOR PREVENTION OF STROKE IN AUSTRIAN ATRIAL FIBRILLATION PATIENTS
    Walter, E.
    Voit, M.
    Eichhober, G.
    VALUE IN HEALTH, 2019, 22 : S548 - S548
  • [23] Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain
    Escolar-Albaladejo, Gines
    Baron-Esquivias, Gonzalo
    Luis Zamorano, Jose
    Betegon-Nicolas, Lourdes
    Canal-Fontcuberta, Cristina
    de Salas-Cansado, Marina
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    ATENCION PRIMARIA, 2016, 48 (06): : 394 - 405
  • [24] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    STROKE, 2013, 44 (06) : 1676 - +
  • [25] Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
    Kamel, Hooman
    Easton, J. Donald
    Johnston, S. Claiborne
    Kim, Anthony S.
    NEUROLOGY, 2012, 79 (14) : 1428 - 1434
  • [26] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [27] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Liu, Chieh-Yu
    Chen, Hui-Chun
    CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 285 - 293
  • [28] AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN FRANCE
    Lanitis, T.
    Bregman, B.
    Maunoury, F.
    Prawitz, T.
    Gaudin, A.
    Cotte, F.
    VALUE IN HEALTH, 2018, 21 : S105 - S105
  • [29] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Clinical Drug Investigation, 2014, 34 : 9 - 17
  • [30] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
12345